Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Unfortunately, the antibody (ID:145297) is no longer available.
Below is a list of antibodies to the same protein target. You may also try your search again using the search box at the top of the page.
Please contact us if you have any questions.
MAPK7 / ERK5
mitogen-activated protein kinase 7
ERK5, a MAPK type protein kinase, mediates growth factor stimulated cell proliferation and muscle cell differentiation. ERK5 differs from other MAP kinases in that it contains a unique loop-12 region within the protein kinase domain which is followed by an extensive C-terminal tail with sequences indicating that it may be targeted to the cytoskeleton. ERK5 is phosphorylated and activated by MEK5 in response to osmotic shock, growth factors and oxidant stress. Activated ERK5 phosphorylates myocyte enhancer factor 2 (MEF2), Sap1, NF-kappaB and p90 ribosomal S6 kinase (RSK/MAPKAPK1). ERK (-/-) mice are defective in blood-vessel and cardiac development. At least four alternatively spliced transcript variants of this gene encoding two distinct protein isoforms, 677 and 815 amino acids, have been identified. ERK5 has been shown to participate in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.